These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 18161868

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Transient disturbance in physeal morphology is associated with long-term effects of nitrogen-containing bisphosphonates in growing rabbits.
    Smith EJ, Little DG, Briody JN, McEvoy A, Smith NC, Eisman JA, Gardiner EM.
    J Bone Miner Res; 2005 Oct; 20(10):1731-41. PubMed ID: 16160731
    [Abstract] [Full Text] [Related]

  • 7. Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model.
    Little DG, McDonald M, Bransford R, Godfrey CB, Amanat N.
    J Bone Miner Res; 2005 Nov; 20(11):2044-52. PubMed ID: 16234978
    [Abstract] [Full Text] [Related]

  • 8. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
    Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P, Holen I.
    Clin Cancer Res; 2008 Jul 15; 14(14):4658-66. PubMed ID: 18628481
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.
    Gasser JA, Green JR, Shen V, Ingold P, Rebmann A, Bhatnagar AS, Evans DB.
    Bone; 2006 Oct 15; 39(4):787-95. PubMed ID: 16844441
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
    Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lippitt J, Green J, Van Marck E, Van Camp B, Vanderkerken K.
    J Bone Miner Res; 2003 Mar 15; 18(3):482-92. PubMed ID: 12619933
    [Abstract] [Full Text] [Related]

  • 13. Temporal changes in bone mass and mechanical properties in a murine model of tumor osteolysis.
    Arrington SA, Schoonmaker JE, Damron TA, Mann KA, Allen MJ.
    Bone; 2006 Mar 15; 38(3):359-67. PubMed ID: 16278105
    [Abstract] [Full Text] [Related]

  • 14. Sequential treatment of ovariectomized mice with bFGF and risedronate restored trabecular bone microarchitecture and mineralization.
    Yao W, Balooch G, Balooch M, Jiang Y, Nalla RK, Kinney J, Wronski TJ, Lane NE.
    Bone; 2006 Sep 15; 39(3):460-9. PubMed ID: 16713415
    [Abstract] [Full Text] [Related]

  • 15. Zoledronic acid prevents loss of trabecular bone after focal irradiation in mice.
    Keenawinna L, Oest ME, Mann KA, Spadaro J, Damron TA.
    Radiat Res; 2013 Jul 15; 180(1):89-99. PubMed ID: 23772924
    [Abstract] [Full Text] [Related]

  • 16. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.
    Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E.
    Prostate Cancer Prostatic Dis; 2005 Jul 15; 8(3):253-9. PubMed ID: 15999121
    [Abstract] [Full Text] [Related]

  • 17. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
    Daubiné F, Le Gall C, Gasser J, Green J, Clézardin P.
    J Natl Cancer Inst; 2007 Feb 21; 99(4):322-30. PubMed ID: 17312309
    [Abstract] [Full Text] [Related]

  • 18. No anti-angiogenic effect of clinical dosing regimens of a single zoledronic acid injection in an experimental bone healing site.
    Biver E, Vieillard MH, Cortet B, Salleron J, Falgayrac G, Penel G.
    Bone; 2010 Mar 21; 46(3):643-8. PubMed ID: 19895916
    [Abstract] [Full Text] [Related]

  • 19. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.
    Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, Schiavon G, Angeletti S, Uzzalli F, Caraglia M, Dicuonzo G, Tonini G.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4482-6. PubMed ID: 17671133
    [Abstract] [Full Text] [Related]

  • 20. Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys.
    Mori H, Tanaka M, Kayasuga R, Masuda T, Ochi Y, Yamada H, Kishikawa K, Ito M, Nakamura T.
    Bone; 2008 Nov 01; 43(5):840-8. PubMed ID: 18718565
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.